Secondary knee osteoarthritis
Other inflammatory Knee Osteoarthritis (e.g. gout, rheumatoid arthritis, etc.)
Patients presenting with gastroesophageal reflux disease, peptic ulcer.
Helicobacter infected patients who have not been treated for eradication (recruitment if negative in re-examination after treatment).
Short bowel syndrome that can cause inflammatory bowel disease (ulcerative colitis, Crohn's disease) and drug absorption disorder.
Intestinal obstruction syndrome
Unexplained abdominal pain
ALT(Alanine aminotransferase) level of liver function test exceeded 5 times of reference range
Total bilirubin level exceeded 2 mg / dL
Serum albumin level less than 2 g / dL
Ascites
Hepatic encephalopathy
Hepatitis B, hepatitis C (excluding healthy carriers) or HIV positive
MDRD(Modification of Diet in Renal Disease) Estimated Glomerular filtration rate less than 60 mL / m2
Patients with hyperkalemia (over 5.5 meq / L)
history of asthma, acute rhinitis, nasal polyps, angioedema, urticaria or allergic reactions to aspirin or other non-steroidal anti-inflammatory drugs(including COX-2 inhibitors).
Malignant tumors other than basal cell or squamous cell carcinoma of the skin, CIN(Cervical Intraepitherial Neoplasia) and CIS(Carcinoma in situ) of the cervix, and intraepithelial carcinoma of other areas Within 5 years of consent date.
Medical history of hypersensitivity to the components of the investigational products. (The components of test drug 1 and 2, including the Rhein-based drug)
Patients with an allergic reaction to sulfonamide.
Patients with galactose intolerance, lapp lactase deficiency or glucose-galactose malabsorption.
Subjects who have not reached the prescribed period after receiving contraindicated medication or treatment before participation in this clinical trial.
Patients receiving contraindicated medication.
Alcohol and other drug abuse cases based on 6 months before screening.
Pregnant women or nursing mothers who are not willing to stop breastfeeding.
(1) Menopause (non-therapy-induced amenorrhea of more than 12 months) Female
(2) Female infertility due to surgery (no ovaries and / or uterus)
(3) If you have sexual intercourse with only one male partner who has been confirmed to have no semen after fertilization.
(4) Female subjects who agreed to abstinence during the clinical trial period.
If the subject is assured of an abstinence throughout the trial period.(e.g. clergy)
However, intermittent abstinence (eg, contraception using ovulation period, symptothermal) or coitus interrupts is not a case of consent for abstinence.
(5) For women of childbearing age, the following methods or methods of contraception use the effective method of contraception to be used during the period of this clinical trial:
Oral contraceptive
The contraceptive patch
Intra uterine device (IUD)
contraceptive implant
contraceptive injection
intrauterine hormonal apparatus
Tubal ligation and infertility surgery
If 30 days have not elapsed after the date of signing of the previous clinical trial or currently participating in other clinical trials.
Patients who are scheduled for surgery during the clinical trial period or who have difficulties in completing the protocol during this clinical trial due to other reasons.
In addition to the above, other diseases that the investigator judges to be inappropriate.

NCT03404479_exc_T1
Qualifier
Secondary
NCT03404479_exc_T2
Condition
knee osteoarthritis
NCT03404479_exc_T3
Qualifier
Other
NCT03404479_exc_T4
Condition
inflammatory Knee Osteoarthritis
NCT03404479_exc_T5
Condition
gout
NCT03404479_exc_T6
Condition
rheumatoid arthritis
NCT03404479_exc_T7
Scope
gout, rheumatoid arthritis
NCT03404479_exc_T8
Scope
Other inflammatory Knee Osteoarthritis
NCT03404479_exc_T9
Condition
gastroesophageal reflux disease
NCT03404479_exc_T10
Condition
peptic ulcer
NCT03404479_exc_T11
Condition
Helicobacter infected
NCT03404479_exc_T12
Negation
not
NCT03404479_exc_T13
Procedure
treated for eradication
NCT03404479_exc_T14
Condition
Short bowel syndrome
NCT03404479_exc_T15
Condition
inflammatory bowel disease
NCT03404479_exc_T16
Mood
can cause
NCT03404479_exc_T17
Qualifier
that can cause inflammatory bowel disease
NCT03404479_exc_T18
Condition
ulcerative colitis
NCT03404479_exc_T19
Condition
Crohn's disease
NCT03404479_exc_T20
Condition
drug absorption disorder
NCT03404479_exc_T21
Scope
ulcerative colitis, Crohn's disease
NCT03404479_exc_T22
Scope
Short bowel syndrome that can cause inflammatory bowel disease
NCT03404479_exc_T23
Condition
Intestinal obstruction syndrome
NCT03404479_exc_T24
Qualifier
Unexplained
NCT03404479_exc_T25
Condition
abdominal pain
NCT03404479_exc_T26
Measurement
ALT(Alanine aminotransferase) level
NCT03404479_exc_T27
Procedure
liver function test
NCT03404479_exc_T28
Value
exceeded 5 times of reference range
NCT03404479_exc_T29
Measurement
Total bilirubin level
NCT03404479_exc_T30
Value
exceeded 2 mg / dL
NCT03404479_exc_T31
Measurement
Serum albumin level
NCT03404479_exc_T32
Value
ess than 2 g / dL
NCT03404479_exc_T33
Condition
Ascites
NCT03404479_exc_T34
Condition
Hepatic encephalopathy
NCT03404479_exc_T35
Condition
Hepatitis B
NCT03404479_exc_T36
Condition
hepatitis C
NCT03404479_exc_T37
Condition
HIV positive
NCT03404479_exc_T38
Negation
excluding
NCT03404479_exc_T39
Condition
healthy carriers
NCT03404479_exc_T40
Qualifier
MDRD(Modification of Diet in Renal Disease)
NCT03404479_exc_T41
Measurement
Estimated Glomerular filtration rate
NCT03404479_exc_T42
Value
less than 60 mL / m2
NCT03404479_exc_T43
Condition
hyperkalemia
NCT03404479_exc_T44
Value
over 5.5 meq / L
NCT03404479_exc_T45
Condition
asthma
NCT03404479_exc_T46
Condition
acute rhinitis
NCT03404479_exc_T47
Condition
nasal polyps
NCT03404479_exc_T48
Condition
angioedema
NCT03404479_exc_T49
Condition
urticaria
NCT03404479_exc_T50
Condition
allergic reactions
NCT03404479_exc_T51
Drug
aspirin
NCT03404479_exc_T52
Qualifier
other
NCT03404479_exc_T53
Drug
non-steroidal anti-inflammatory drugs
NCT03404479_exc_T54
Drug
COX-2 inhibitors
NCT03404479_exc_T55
Scope
aspirin or other non-steroidal anti-inflammatory drugs(including COX-2 inhibitors)
NCT03404479_exc_T56
Condition
Malignant tumors
NCT03404479_exc_T57
Negation
other than
NCT03404479_exc_T58
Condition
uamous cel  skin, CIN(Cervical 
NCT03404479_exc_T59
Condition
squamous cell carcinoma of the skin
NCT03404479_exc_T60
Scope
basal cell or squamous cell carcinoma of the skin
NCT03404479_exc_T61
Condition
CIN(Cervical Intraepitherial Neoplasia)
NCT03404479_exc_T62
Condition
CIS(Carcinoma in situ) of the cervix
NCT03404479_exc_T63
Condition
intraepithelial carcinoma
NCT03404479_exc_T64
Temporal
Within 5 years of consent date
NCT03404479_exc_T65
Reference_point
consent date
NCT03404479_exc_T66
Scope
Malignant tumors other than basal cell or squamous cell carcinoma of the skin, CIN(Cervical Intraepitherial Neoplasia) and CIS(Carcinoma in situ) of the cervix, and intraepithelial carcinoma
NCT03404479_exc_T67
Condition
hypersensitivity
NCT03404479_exc_T68
Drug
components of the investigational products
NCT03404479_exc_T69
Drug
components of test drug 1
NCT03404479_exc_T70
Drug
t drug 1 and 2, includi R
NCT03404479_exc_T71
Drug
Rhein-based drug
NCT03404479_exc_T72
Scope
components of test drug 1 and 2, including the Rhein-based drug
NCT03404479_exc_T73
Condition
allergic reaction
NCT03404479_exc_T74
Drug
sulfonamide
NCT03404479_exc_T75
Condition
galactose intolerance
NCT03404479_exc_T76
Condition
lapp lactase deficiency
NCT03404479_exc_T77
Condition
glucose-galactose malabsorption
NCT03404479_exc_T79
Drug
contraindicated medication
NCT03404479_exc_T80
Condition
 abus  mon
NCT03404479_exc_T81
Condition
drug abuse
NCT03404479_exc_T82
Temporal
6 months before screening
NCT03404479_exc_T83
Scope
Alcohol and other drug abuse
NCT03404479_exc_T85
Condition
Menopause
NCT03404479_exc_T86
Qualifier
non-therapy-induced
NCT03404479_exc_T87
Condition
amenorrhea
NCT03404479_exc_T88
Multiplier
more than 12 months
NCT03404479_exc_T89
Scope
non-therapy-induced amenorrhea of more than 12 months
NCT03404479_exc_T90
Person
Female
NCT03404479_exc_T91
Person
Female
NCT03404479_exc_T92
Condition
infertility
NCT03404479_exc_T93
Qualifier
due to surgery
NCT03404479_exc_T94
Condition
no ovaries
NCT03404479_exc_T95
Condition
s) exual
NCT03404479_exc_T96
Scope
infertility due to surgery
NCT03404479_exc_T97
Scope
no ovaries and / or uterus
NCT03404479_exc_T103
Drug
Oral contraceptive
NCT03404479_exc_T107
Device
contraceptive patch
NCT03404479_exc_T108
Device
Intra uterine device (IUD)
NCT03404479_exc_T109
Device
contraceptive implant
NCT03404479_exc_T110
Device
contraceptive injection
NCT03404479_exc_T111
Device
intrauterine hormonal apparatus
NCT03404479_exc_T112
Procedure
Tubal ligation
NCT03404479_exc_T113
Procedure
infertility surgery